Datasheet: C12CA.1

BATCH NUMBER 163333

Description:	BABY RABBIT COMPLEMENT
Name:	BABY RABBIT COMPLEMENT
Format:	Serum
Product Type:	Serum
Quantity:	1 ml

Product Details

Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit www.bio-

	Yes	No	Not Determined	Suggested Dilution
Functional Assays (1)	▪			
Immunoassay	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

(1) **This product is not sold as sterile but can be sterilized by filtration if necessary. It is preferable to dilute the complement to a final working concentration before filtration in order to minimize loss of volume.**

Product Form

Baby rabbit serum - lyophilized

Reconstitution

Reconstitute with 1.0 ml ice cold distilled water

Preservative Stabilisers

None present

Product Information

Baby rabbit complement serum preparation is intended for use as a source of rabbit complement for cytotoxicity assays.

References

1. De clercq, L. *et al.* (1997) An anti-adipocyte monoclonal antibody is cytotoxic to porcine preadipocytes *in vitro* and depresses the development of pig adipose tissue. J Anim Sci. 75 (7): 1791-7.

2. Anderson, L.D. Jr *et al.* (1999) Enhancement of graft-versus-tumor activity and graft-versus-host disease by pretransplant immunization of allogeneic bone marrow donors with a recipient-derived tumor cell vaccine. Cancer Res. 59 (7): 1525-30.

3. Lidington, E.A. *et al.* (2000) Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase C-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood. 96 (8): 2784-92.
4. Mason, J.C. *et al.* (2002) bFGF and VEGF synergistically enhance endothelial cytoprotection via decay-accelerating factor induction. Am J Physiol Cell Physiol. 282: C578-87.
5. Mason, J.C. *et al.* (2002) Statin-induced expression of decay-accelerating factor protects vascular endothelium against complement-mediated injury. Circ Res. 91 (8): 696-703.
6. Li, S.H. *et al.* (2004) C-reactive protein upregulates complement-inhibitory factors in endothelial cells. Circulation. 109: 833-6.
7. Newcombe, J. *et al.* (2004) Infection with an avirulent phoP mutant of *Neisseria meningitidis* confers broad cross-reactive immunity. Infect Immun. 72: 338-44.
8. Sancho, D. *et al.* (2006) CD69 targeting differentially affects the course of collagen-induced arthritis. J Leukoc Biol. 80: 1233-41.
9. Hyams, C. *et al.* (2010) *Streptococcus pneumoniae* resistance to complement-mediated immunity is dependent on the capsular serotype. Infect Immun. 78: 716-25.
10. Hung, M.C. *et al.* (2011) The *Neisseria meningitidis* Macrophage Infectivity Potentiator Protein Induces Cross-Strain Serum Bactericidal Activity and Is a Potential Serogroup B Vaccine Candidate. Infect Immun. 79: 3784-91.
11. Lee, S.J. *et al.* (2012) Identification of a common immune signature in murine and human systemic Salmonellosis. Proc Natl Acad Sci U S A. 109 (13): 4998-5003.
12. Hung MC *et al.* (2013) The adhesin complex protein (ACP) of *Neisseria meningitidis* is a new adhesin with vaccine potential. MBio. 4 (2): pii: e00041-13.
13. Goh, Y.S. & MacLennan, C.A. (2013) Invasive African nontyphoidal Salmonella requires high levels of complement for cell-free antibody-dependent killing. J Immunol Methods. 387 (1-2): 121-9.
14. Goh YS *et al.* (2016) Bactericidal Immunity to *Salmonella* in Africans and Mechanisms Causing Its Failure in HIV Infection. PLoS Negl Trop Dis. 10 (4): e0004604.
15. Humbert MV *et al.* (2016) Vaccine Potential and Diversity of the Putative Cell Binding Factor (CBF, NMB0345/NEIS1825) Protein of *Neisseria meningitidis*. PLoS One. 11 (8): e0160403.
16. Dierckx de Casterlé I *et al.* (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. Cancer Immunol Immunother. 67 (4): 589-603.
17. Valton, J. *et al.* (2018) A Versatile Safeguard for Chimeric Antigen Receptor T-Cell Immunotherapies. Sci Rep. 8 (1): 8972.
18. Dierckx de Casterlé, I. *et al.* (2018) Reduction of myeloid-derived suppressor cells reinforces the anti-solid tumor effect of recipient leukocyte infusion in murine neuroblastoma-bearing allogeneic bone marrow chimeras. Cancer Immunol Immunother. 67 (4): 589-603.
19. Nganje, C.N. *et al.* (2019) PepN is a non-essential, cell wall-localized protein that contributes to neutrophil elastase-mediated killing of *Streptococcus pneumoniae*. PLoS One. 14 (2): e0211632.
20. Cuesta-Mateos, C. *et al.* (2020) CCR7 as a novel therapeutic target in t-cell PROLYMPHOCYTIC leukemia Biomarker Research.8, 54.

21. Mosti, L. *et al.* (2021) Targeted multi-epitope switching enables straightforward positive/negative selection of CAR T cells. Gene Ther. 28 (9): 602-12.

Storage	Prior to reconstitution store at +4^{o}C. Following reconstitution store at +4^{o}C for 1 hour or aliquot and store at -70^{o}C for longer. This product should be stored undiluted. Avoid repeated freezing and thawing as this may denature the product. Should this product contain a precipitate we recommend microcentrifugation before use.
Guarantee	Guaranteed until date of expiry. Please see product label.
Health And Safety	Material Safety Datasheet documentation #10288 available at: